Safety and antitumor activity of arsenic trioxide (ATO) plus infusional 5-FU, leucovorin and irinotecan (FOLFIRI) as second-line treatment for refractory metastatic colorectal cancer: Preliminary results from a pilot study

被引：0
|
作者：
Chaudhuri, T. [1 ]
Lakshmaiah, K. C. [1 ]
Babu, K. G. [1 ]
Dasappa, L. [1 ]
Jacob, L. A. [1 ]
Babu, M. C. S. [1 ]
Rudresha, A. H. [1 ]
Lokesh, K. N. [1 ]
Rajeev, L. K. [1 ]
机构：
[1] Kidwai Mem Inst Oncol, Med Oncol, Bangalore, Karnataka, India
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
150P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SECOND-LINE CHEMOTHERAPY WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) IN RELAPSED OR METASTATIC GASTRIC CANCER: LESSONS FROM THE CLINICAL PRACTICE
    Bittoni, Alessandro
    Pistelli, Mirco
    Scartozzi, Mario
    Galizia, Eva
    Berardi, Rossana
    Cascinu, Stefano
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [42] Extended phase I study of a weekly schedule of irinotecan (CPT-11), leucovorin and infusional 5-FU as first-line chemotherapy in metastatic colorectal cancer.
    Vanhoefer, U
    Harstrick, A
    Achterrath, W
    Lipp, R
    Mayer, S
    Schöffski, P
    Köhne, CH
    Hossfeld, KD
    Wilke, H
    Seeber, S
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 : 3799S - 3799S
  • [43] Final results from PRECEPT: efficacy and safety of second-line treatment with panitumumab and FOLFIRI in patients with metastatic colorectal cancer (mCRC)
    Cohn, A.
    Smith, D. A.
    Neubauer, M. A.
    Richards, D.
    Watkins, D. L.
    Zhang, K.
    Yassine, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 347 - 347
  • [44] Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
    Peeters, M.
    Price, T. J.
    Cervantes, A.
    Sobrero, A. F.
    Ducreux, M.
    Hotko, Y.
    Andre, T.
    Chan, E.
    Lordick, F.
    Punt, C. J. A.
    Strickland, A. H.
    Wilson, G.
    Ciuleanu, T. E.
    Roman, L.
    Van Cutsem, E.
    Tian, Y.
    Sidhu, R.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (01) : 107 - 116
  • [45] Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups.
    Fyfe, GA
    Hurwitz, H
    Fehrenbacher, L
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Kabbinavar, F
    Holmgren, E
    Novotny, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 274S - 274S
  • [46] Randomized phase II study of combined infusional leucovorin sodium (LVNa) and 5-FU versus the sequential administration of leucovorin calcium (LVCa) followed by 5-FU with irinotecan or oxaliplatin in patients (pts) with metastatic colorectal cancer (mCRC)
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezael
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Song Xie
    Guoping Han
    Zhikun Fan
    Lifeng He
    Wenbing Xu
    Zhen Qin
    [J]. Medical Oncology, 2014, 31
  • [48] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Xie, Song
    Han, Guoping
    Fan, Zhikun
    He, Lifeng
    Xu, Wenbing
    Qin, Zhen
    [J]. MEDICAL ONCOLOGY, 2014, 31 (07)
  • [49] Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI)
    Ding, Hong-hua
    Wu, Wei-dong
    Jiang, Tao
    Cao, Jun
    Ji, Zheng-yi
    Jin, Jia-huan
    Wang, Jing-jue
    Song, Wei-feng
    Wang, Li-wei
    [J]. TUMOR BIOLOGY, 2015, 36 (05) : 3361 - 3369
  • [50] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third-line treatment of metastatic colorectal cancer (mCRC): Safety and efficacy analysis.
    Smith, D. M.
    Legoux, J.
    Brunet, R.
    Adhoute, X.
    Blanc, J.
    Fonck, M.
    Vendrely, V.
    Becouarn, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
12345